We are delighted to announce the appointment of Jonathan Morgan as LifeArc's first Chief Medical Officer with effect from January 2025. As CMO, Jonathan will play a crucial role in shaping our clinical research agenda and supporting clinical development programmes.

We’re in the running for the Smiley Charity Film Awards! With Asthma + Lung UK, our film highlights the struggles of living with chronic lung conditions like bronchiectasis. Watch Felix’s story and vote for us! 👉 t.ly/W5uLV Charity Film Awards

We are delighted to announce the appointment of Ghada Zoubiane and Kelly Chibale respectively as our new Head and Chair of Global Health - bringing their wealth of experience driving vital, innovative research to help propel the improvement of global health outcomes.

Our Chief Project and Portfolio Officer, Karen Skinner, and Chief Medical Officer, Jonathan Morgan, were invited to The White House yesterday to participate in a panel at the #WhiteHouseCGT forum.

Today we're announcing we are working with Cleveland Clinic - one of the largest healthcare researchers in the world - on a 10-year master services agreement to develop new monoclonal antibody treatments for patients with high unmet medical needs: t.ly/vdKj_

The NeurEYE research team has collected almost a million eye scans from high-street opticians to develop a digital tool that utilises AI to predict an individual's risk of dementia. Find out more: t.ly/yRvJY The University of Edinburgh Glasgow Caledonian University Photo: Andrew Perry

We need to work together to translate discoveries into tangible therapies for people with rare diseases. This network of 4 Translational Centres for Rare Diseases will support the development of new tests, treatments and hopefully cures. youtu.be/rZtSkSSJc50

The LifeArc Translational Centres for Rare Disease will work together to get new tests and treatments to people living with a rare disease faster. An exciting moment for rare disease research in the UK.

'Future generations need cure' for brain disorder bbc.in/4hzHPgm

This is a powerful example of the kind of research LifeArc supports to transform the lives of people living with a rare disease. The DefINe Trial is testing a repurposed drug to see if it could treat an ultra-rare disease that leaves people 'trapped in their own bodies.'

📆The Translational Science Summit on MND & Rare Dementias is just over 2 weeks away! We're excited to announce Jill Douglas will be joining us to deliver the closing keynote session. #RareNeuro Join the event's waitlist here: mnd.translationalsciencesummit.org/home

Just 15 minutes until the first-ever LifeArc Translational Science Summit on MND and Rare Dementias officially begins! Our attendees are coming in thick and fast as we await the opening session. Follow along on the day using #RareNeuro #MND #Neurodegeneration

A moving open to the LifeArc Translational Science Summit on Motor Neuron Disease and Rare Dementias with a video from David Setters on the need for more research into these conditions. Sam Barrell drove this message home in her opening plenary. A great start! #rareneuro

And we are off! 🚀 Sam Barrell kicked off the first-ever LifeArc Translational Science Summit on MND and Rare Dementias with an opening session sharing our vision and work to shape the future of translational science for MND and rare dementias. #RareNeuro #MND #RareDementias

Happy International Women's Day! We are committed to gender equality and are proud of our women in senior leadership. We asked them to share their advice for those entering life sciences or aiming for leadership. ✨ #IWD2025

It's #BritishScienceWeek - a chance to celebrate and promote the fascinating field we work in by sharing some of the things we love about it. Hear from some of our scientists as they share what excites them most about their work!

“The calibre of international investors in the $72 million Series A is testament to the potential of Maxion’s unique approach, which we believe can be transformative in the treatment of multiple ion channel- and GPCR-driven diseases.” Sohaib Mir, Partner, LifeArc Ventures.

Our Rare Disease Chair, Amit Nathwani, shares why it's so important that we #ChangeTheRareFuture for the nearly 3.5 million people with rare diseases in the UK at our report launch in Westminster. Genetic Alliance UK

"This Government remains committed to improving the lives of people with rare diseases… This is not something that [we] can do alone. We will do it in partnership with experts and with people with rare diseases and their families." Ashley Dalton MP #ChangeTheRareFuture

"The future of medicine – for all of us – is more personalised, more precise, and more patient-led... We must act today to work together and to transform the system for the millions of people living with rare diseases." -Sam Barrell, LifeArc CEO #ChangeTheRareFuture